LUNSUMIO Market Summary

Key Factors Driving LUNSUMIO Growth

1. Strong efficacy and durable responses in relapsed/refractory follicular lymphoma (FL):

LUNSUMIO is a CD20×CD3 T-cell-engaging bispecific antibody that redirects T cells to CD20-positive malignant B cells. In the pivotal GO29781 study, the drug produced an 80% overall response rate and 60% complete response rate in patients with R/R FL after ≥2 prior therapies. With approximately 3 years of follow-up, the ORR remained 77.8%, CR rate was 60%, median duration of response was 35.9 months, and median PFS was 24.0 months. These durable outcomes provide an important foundation for continued adoption in later-line FL.

2. Subcutaneous LUNSUMIO VELO is expanding convenience and potentially broadening utilization:

Roche developed a subcutaneous formulation, LUNSUMIO VELO, designed to substantially reduce administration burden. The FDA approved the formulation in December 2025, and the European Commission also granted authorization. Roche reports that administration time can be reduced from approximately 2–4 hours with IV LUNSUMIO to about 1 minute with the SC formulation. The 2026 Phase II publication demonstrated pharmacokinetic comparability with IV administration, supporting the formulation's clinical use. A shorter administration time and potential outpatient/community use can facilitate adoption and improve treatment convenience.

3. Potential expansion into large B-cell lymphoma provides another major growth opportunity:

The Phase III SUNMO study evaluated subcutaneous LUNSUMIO + Polivy (polatuzumab vedotin) in R/R LBCL patients who were not eligible for transplant. The combination reduced the risk of progression or death by 59% (HR 0.41) versus R-GemOx, with median PFS of 11.5 months versus 3.8 months. ORR was 70.3% versus 40.0%, while CR was 51.4% versus 24.3%. Roche submitted the combination to regulators, and the FDA accepted the supplemental BLA in June 2026. Regulatory approval would therefore create another commercial indication beyond FL.

4. Off-the-shelf, fixed-duration treatment can differentiate LUNSUMIO from individualized cellular therapies:

Unlike CAR-T therapies that require patient-specific cell collection and manufacturing, LUNSUMIO is an off-the-shelf biologic. The established FL regimen is fixed-duration, with patients generally receiving eight cycles and discontinuing after a complete response. Long-term data support the feasibility of this approach: 49 of 54 patients who achieved CR remained in CR at the end of treatment in the three-year analysis, and the estimated 30-month remission rate among complete responders was 72.4%. This combination of ready availability, finite treatment duration and durable responses may support utilization in appropriate patients.

5. Increasing geographic penetration is contributing to revenue growth:

Roche reported that LUNSUMIO was approved for R/R FL in more than 60 countries by 2025. Commercial momentum has been visible in Roche's reported sales: quarterly sales increased from CHF 16 million in Q1 2024 (+21% CER) to CHF 21 million in Q1 2025 (+25% CER). Roche's 2026 reporting also specifically identified continued LUNSUMIO uptake in Japan as a contributor to pharmaceutical sales growth. Further rollout of the SC formulation and potential new indications could support additional geographic and commercial expansion.

LUNSUMIO Recent Developments

In September 2026, Roche announced that the Phase III CELESTIMO trial of LUNSUMIO + lenalidomide versus rituximab + lenalidomide in patients with R/R FL after at least one prior line of treatment met its primary PFS endpoint at interim analysis. Roche reported a statistically significant and clinically meaningful reduction in the risk of disease progression. The data are planned for presentation and regulatory submissions.

“LUNSUMIO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of LUNSUMIO for approved indication like Follicular lymphoma and Non-Hodgkin’s lymphoma; as well as potential indication like Diffuse large B cell lymphoma, Marginal zone B-cell lymphoma, Systemic lupus erythematosus, and Chronic lymphocytic leukaemia in the 7MM. A detailed picture of LUNSUMIO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the LUNSUMIO for approved and potential indications. The LUNSUMIO market report provides insights about LUNSUMIO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LUNSUMIO performance, future market assessments inclusive of the LUNSUMIO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LUNSUMIO sales forecasts, along with factors driving its market.

LUNSUMIO Drug Summary

LUNSUMIO is a CD20xCD3 bispecific T-cell engager antibody developed by Genentech, a member of the Roche Group, for the treatment of certain patients with relapsed or refractory follicular lymphoma. It is designed to simultaneously bind CD20 on B cells and CD3 on T cells, bringing T cells into close proximity with malignant B cells and activating T-cell-mediated cytotoxicity, resulting in targeted destruction of CD20-expressing tumor cells. LUNSUMIO is administered through intravenous infusion using a step-up dosing schedule during the first cycle to reduce the risk and severity of cytokine release syndrome (CRS), followed by less frequent maintenance dosing. In the United States, LUNSUMIO is approved for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, with its accelerated approval based on overall response rate and duration of response. Key safety concerns include CRS, infections, neutropenia, hypophosphatemia, hypokalemia, and immune effector cell-associated neurotoxicity syndrome (ICANS), requiring appropriate monitoring and supportive care during treatment. The report provides LUNSUMIO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LUNSUMIO Market Report

The report provides insights into:

• A comprehensive product overview including the LUNSUMIO MoA, description, dosage and administration, research and development activities in approved indications like Follicular lymphoma and Non-Hodgkin’s lymphoma; as well as potential indication like Diffuse large B cell lymphoma, Marginal zone B-cell lymphoma, Systemic lupus erythematosus, and Chronic lymphocytic leukaemia.
• Elaborated details on LUNSUMIO regulatory milestones and other development activities have been provided in LUNSUMIO market report.
• The report also highlights LUNSUMIO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The LUNSUMIO market report also covers the patents information, generic entry and impact on cost cut.
• The LUNSUMIO market report contains current and forecasted LUNSUMIO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LUNSUMIO market report also features the SWOT analysis with analyst views for LUNSUMIO in approved and potential indications.

Methodology

The LUNSUMIO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUNSUMIO Analytical Perspective by DelveInsight

• In-depth LUNSUMIO Market Assessment

This LUNSUMIO sales market forecast report provides a detailed market assessment of LUNSUMIO for approved indication like Follicular lymphoma and Non-Hodgkin’s lymphoma; as well as potential indication like Diffuse large B cell lymphoma, Marginal zone B-cell lymphoma, Systemic lupus erythematosus, and Chronic lymphocytic leukaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LUNSUMIO sales data uptil 2034.

• LUNSUMIO Clinical Assessment

The LUNSUMIO market report provides the clinical trials information of LUNSUMIO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

LUNSUMIO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LUNSUMIO Market Potential & Revenue Forecast

• Projected market size for the LUNSUMIO and its key indications
• Estimated LUNSUMIO sales potential (LUNSUMIO peak sales forecasts)
• LUNSUMIO Pricing strategies and reimbursement landscape

LUNSUMIO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LUNSUMIO Market positioning compared to existing treatments
• LUNSUMIO Strengths & weaknesses relative to competitors

LUNSUMIO Regulatory & Commercial Milestones

• LUNSUMIO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LUNSUMIO Clinical Differentiation

• LUNSUMIO Efficacy & safety advantages over existing drugs
• LUNSUMIO Unique selling points

LUNSUMIO Market Report Highlights

• In the coming years, the LUNSUMIO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LUNSUMIO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUNSUMIO’s dominance.
• Other emerging products for Follicular lymphoma and Non-Hodgkin’s lymphoma; as well as potential indication like Diffuse large B cell lymphoma, Marginal zone B-cell lymphoma, Systemic lupus erythematosus, and Chronic lymphocytic leukaemia are expected to give tough market competition to LUNSUMIO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUNSUMIO in approved and potential indications.
• Analyse LUNSUMIO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LUNSUMIO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LUNSUMIO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of LUNSUMIO? How strong is LUNSUMIO’s clinical and commercial performance?
• What is LUNSUMIO’s clinical trial status in each individual indications such as Follicular lymphoma and Non-Hodgkin’s lymphoma; as well as potential indication like Diffuse large B cell lymphoma, Marginal zone B-cell lymphoma, Systemic lupus erythematosus, and Chronic lymphocytic leukaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUNSUMIO Manufacturers?
• What are the key designations that have been granted to LUNSUMIO for approved and potential indications? How are they going to impact LUNSUMIO’s penetration in various geographies?
• What is the current and forecasted LUNSUMIO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LUNSUMIO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LUNSUMIO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is LUNSUMIO? What is the duration of therapy and what are the geographical variations in cost per patient?